

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD**

FRESENIUS KABI USA LLC

Petitioner,

v.

CUBIST PHARMACEUTICALS LLC

Patent Owner.

Case: IPR2015-01570

Patent No. 8,058,238

**PATENT OWNER'S PRELIMINARY RESPONSE
UNDER 37 C.F.R. § 42.107**

TABLE OF CONTENTS

	PAGE
I. INTRODUCTION	1
A. State of the Art Prior to the Invention	2
B. Description of the Invention.....	4
II. DEFINITION OF ONE OF ORDINARY SKILL IN THE ART	6
III. INTERPRETATION OF PRODUCT-BY-PROCESS CLAIMS	6
IV. THE PETITION SHOULD BE DENIED BECAUSE GROUND 1 DOES NOT ADDRESS EVERY LIMITATION OF CLAIM 98.....	8
A. The Process Limitations of Claim 98 Impart Structural and Functional Differences to the Claimed Product.....	8
B. The Petition Fails to Establish a Lack of Structural and Functional Differences	11
C. The Petition Improperly Ignores the Process Limitations of Claim 98	12
V. CONCLUSION.....	14

TABLE OF AUTHORITIES

	Page(s)
FEDERAL CASES	
<i>Amgen Inc. v. F. Hoffman-La Roche Ltd</i> , 580 F.3d 1340 (Fed. Cir. 2009)	7, 11
<i>Biodelivery Scis. Int’l, Inc. v. Monosol RX, LLC</i> , IPR2015-00168	7, 11
<i>Corning Inc. v. DSM IP Assets B.V.</i> , IPR2013-00052	7, 10
<i>Greenliant Sys., Inc. v. Xicor LLC</i> , 692 F.3d 1261 (Fed. Cir. 2012)	7
FEDERAL STATUTES	
35 U.S.C. § 314	2
REGULATIONS	
37 C.F.R. § 42.104 (b)(4)	14
37 C.F.R. § 42.107	16
37 C.F.R. § 42.108	2
53 Fed. Reg. 5,044 (Feb. 19, 1988)	15
53 Fed. Reg. 5,044, 5,045 (Feb. 19, 1988) (Ex. 2003)	3
OTHER AUTHORITIES	
U.S. Patent No. 4,874,843	passim
U.S. Patent No. 8,058,238	passim
U.S. Patent No. RE39,071	3

I. INTRODUCTION

Patent Owner Cubist Pharmaceuticals LLC's ("Cubist") U.S. Patent No. 8,058,238 (the "'238 patent") claims highly purified daptomycin compositions and pharmaceutical compositions thereof. The '238 patent discloses techniques that allow for the production of highly purified daptomycin compositions on a commercial scale. Previous purification techniques for daptomycin did not effectively remove these harmful impurities and resulted in extremely low yields, which made commercial-scale production of daptomycin infeasible.

Fresenius Kabi USA LLC ("Fresenius") filed the present Petition to invalidate certain claims of the '238 patent as anticipated. Subsequently, the Board granted a joint motion to limit the present Petition to claim 98. *See* IPR2015-01570, Paper 12 (September 15, 2015). Therefore, the Petition is now narrowed to claim 98, challenged in Ground 1. The other claims and, consequently, Ground 2 are no longer at issue. Nevertheless, Fresenius's Petition, even as narrowed, should not be instituted as there is no reasonable likelihood that Petitioner will prevail on at least one claim.

Ground 1 ignores the process limitations of the challenged product-by-process claim, without sufficiently establishing that these limitations do not impart structural and functional differences to the claimed product. Ground 1 thus improperly fails to address each limitation of the challenged claim. This

deficiency defeats Fresenius's proposed ground, such that there is no reasonable likelihood that the Petitioner will prevail on at least one claim, and the Board should not institute review. 35 U.S.C. § 314; 37 C.F.R. § 42.108. Patent Owner also disagrees with Petitioner on the merits, but will not otherwise address the substance of Petitioner's arguments in this paper.

A. State of the Art Prior to the Invention

Daptomycin is a potent antibiotic effective for treating serious infections caused by certain Gram-positive bacteria including *Staphylococcus aureus* and methicillin-resistant *Staphylococcus aureus* ("MRSA"). See CUBICIN® (daptomycin for injection) label approved November 26, 2014, at 2 (Ex. 2001). Daptomycin is obtained by fermenting the soil microorganism *Streptomyces roseosporus* (*S. roseosporus*). '238 patent at 1:60-63 (Ex. 1001). Fermenting *S. roseosporus* produces a complex mixture containing many undesirable compounds. Separating daptomycin from these compounds is difficult, particularly while obtaining quantities on a commercial scale.

The mixture resulting from fermentation of *S. roseosporus* may contain, among other things, endotoxins, saponins, and a group of daptomycin-related impurities identified in Table 3 of the '238 patent. *Id.* at 33:63-34:19. Each of these substances is undesirable in a pharmaceutical daptomycin composition. Even very small amounts of endotoxins (also referred to as pyrogens) can cause fever

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.